1. Home
  2. OFS vs ACET Comparison

OFS vs ACET Comparison

Compare OFS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Capital Corporation

OFS

OFS Capital Corporation

N/A

Current Price

$3.67

Market Cap

54.3M

Sector

Finance

ML Signal

N/A

ACET

Adicet Bio Inc.

N/A

Current Price

$3.39

Market Cap

33.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OFS
ACET
Founded
2001
1947
Country
United States
United States
Employees
N/A
102
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.3M
33.5M
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
OFS
ACET
Price
$3.67
$3.39
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $34.83
AVG Volume (30 Days)
76.1K
★ 187.5K
Earning Date
10-29-2026
11-13-2026
Dividend Yield
★ 16.96%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.99
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$0.46
52 Week High
$5.81
$9.97

Technical Indicators

Market Signals
Indicator
OFS
ACET
Relative Strength Index (RSI) 38.98 18.83
Support Level $3.51 N/A
Resistance Level $4.07 $9.59
Average True Range (ATR) 0.14 0.34
MACD -0.03 -0.02
Stochastic Oscillator 29.39 3.39

Price Performance

Historical Comparison
OFS
ACET

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: